Although some outcomes showed small to medium effect sizes, these results must be interpreted cautiously given the presence of uncertainty factors, including considerable heterogeneity and moderate ...

Investigators from Hackensack Meridian John Theurer Cancer Center (JTCC)—a leading research partner of the NCI-designated ...

Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory ...

Background Eisenmenger syndrome (ES) is a severe and fatal complication of uncorrected congenital heart disease characterised ...

Final 5-year data from the phase 2 2102-HEM-101 trial (NCT02719574) show that olutasidenib (Rezlidhia) delivered sustained ...

The gene therapy market for ocular rare diseases is expanding rapidly as breakthroughs in viral vectors (like AAV) and gene-editing tools enable one-time, disease-modifying treatments for previously ...

The owner of LED-light therapy mask CurrentBody--which listed on the London Stock Exchange last month--on Wednesday attributed its performance to an ever-increasing awareness of the at-home ...

TG Therapeutics, Inc. has seen rapid enrolment of ENHANCE study, which could allow simplified dosing regime of IV Briumvi.

New Real-World Data support the effect of D-cycloserine (NRX-101 active ingredient) in doubling the effectiveness of Transcranial Magnetic Stimulation (TMS). Company has expanded access program for ...

Tania Markovic MBBS PhD FRACP; Jennifer L. Miller, MD; Elizabeth Roof, H.S.P., M.A.; and Theresa V. Strong, PhD; ...

Methods: We conducted a real-world observational study of 244 patients receiving group-based CBT in 5 of the United Kingdom’s National Health Service Talking Therapies services, comparing 150 (61.5%) ...

Treatment with Endeavor Biomedicines’ experimental oral therapy ENV-101 (taladegib) improved lung function in people with IPF ...